Saturday 17 October 2026
Export ONCO’s income statement to Excel — free account
Onconetix, Inc.
ONCO Healthcare Biotechnology
Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024. In the quarter to June 2026, revenue fell 83.9%, EPS grew 99.5% and free cash flow fell 36.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.48
0.07
−12.73%
Follow ONCO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 1.31 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.92 | 1.27 | 1.80 | 3.57 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.32) | (0.44) | (0.47) | (1.37) | |
P/B ratio |
0.19 | 0.08 | 0.09 | 1.30 | |
Price to Tangible BV |
0.66 | 0.61 | 0.00 | 0.00 | |
EV/Sales |
(5.09) | (3.62) | (4.46) | 2.98 | |
EV/EBITDA |
0.20 | 0.17 | 0.21 | 0.00 | |
EV/Operating CF |
0.32 | 0.27 | 0.38 | (0.49) | |
EV/FCF |
0.32 | 0.27 | 0.37 | (0.48) | |
Quick Ratio |
2.02 | 1.23 | 0.61 | 0.05 | |
Current Ratio |
2.21 | 1.41 | 0.66 | 0.08 | |
Net Debt/EBITDA |
2.18 | 0.36 | 4.10 | 0.43 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.04 | 0.03 | 0.03 | |
Operating CF/Net income |
0.67 | 0.50 | (0.55) | 0.36 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(620.64) | (4,648.09) | (305.10) | (6.89) | |
Research and Development Expense of Revenue |
19.88% | 236.28% | 8.00% | (1.05%) | |
Selling, General and Administrative Expense of Revenue |
13,132.75% | 9,485.12% | 495.65% | 770.93% | |
Intangible Assets out of Total Assets |
0.59 | 0.69 | 0.74 | 0.92 | |
Share Based Compensation of Revenue |
43.27% | 103.72% | 1.42% | 3.23% | |
Graham Net Nets |
1.40 | 1.33 | (2.11) | (3.43) | |
Graham Number |
183.10 | 218.86 | 0.00 | 17,509.28 | |
Earnings Yield |
21,957.52% | 76.51% | (2,778.54%) | 72,974.69% | |
Free Cash Flow Yield |
(407.85%) | (1,048.72%) | (661.95%) | (172.42%) | |
Revenue per Share |
0.01 | 0.34 | 16.15 | 10.81 | |
Operating CF per Share |
(0.86) | (33.73) | (164.39) | (113.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.86) | (33.73) | (164.39) | (113.09) | |
Cash per Share |
2.65 | 59.08 | 277.70 | 29.77 | |
Shareholders Equity per Share |
6.01 | 186.75 | 838.54 | 120.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.01 | 186.75 | 838.54 | 120.07 | |
Free Cash Flow |
(1.92) | (2.12) | (3.09) | (3.18) | |
Working Capital |
3.57 | 1.26 | (3.07) | (15.00) | |
Net Current Asset Value |
3.56 | 1.24 | (3.10) | (15.00) | |
EV/EBIT |
0.20 | 0.17 | 0.20 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.01 | 0.03 | 0.19 | 0.05 | |
Average Payables |
2.21 | 2.06 | 2.77 | 2.96 | |
Average Inventory |
0.18 | 0.15 | 0.11 | 0.14 | |
Average Assets |
17.77 | 16.80 | 26.55 | 40.80 | |
Average Common Equity |
9.69 | 7.87 | 12.15 | 22.20 |
Columns are period end dates